Antibodies that bind to truncated mutant calreticulin and drugs for diagnosis, prevention or treatment of bone marrow proliferative tumors

By developing specific antibodies that identify the cleavage site of mutant CALR proteins, the problem of detecting and treating MPN in the prior art has been solved, and the diagnostic and therapeutic effects have been significantly improved.

CN113508140BActive Publication Date: 2024-11-19JUNTENDO EDUCATIONAL FOUNDATION +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202080017462.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-02-28
Filing Date
2020-02-28
Publication Date
2024-11-19
Estimated Expiration
2040-02-28

AI Technical Summary

Technical Problem

The prior art is difficult to accurately detect mutant CALR proteins caused by CALR gene mutations in bone proliferative tumors, resulting in poor diagnosis and treatment effects.

Method used

A specific antibody was developed that can recognize and bind to the cleavage site of the mutant CALR protein, which is closer to the short amino acid sequence on the amino terminal side, which improves the detection sensitivity of the mutant CALR protein on the cell surface and inhibits the cleavage of the mutant CALR protein. To enhance the therapeutic effect.

Benefits of technology

The diagnostic sensitivity of MPN is significantly improved and a more effective treatment plan is provided, enhancing the efficacy of therapeutic drugs by specifically identifying and targeting mutant CALR proteins.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0003234075900000011
    Figure HDA0003234075900000011
  • Figure HDA0003234075900000012
    Figure HDA0003234075900000012
  • Figure HDA0003234075900000013
    Figure HDA0003234075900000013
Patent Text Reader

Abstract

The present invention provides a drug for diagnosing, preventing and treating bone marrow proliferative tumors. An antibody or a functional fragment thereof that binds to a truncated mutant CALR protein, and a drug for diagnosing, preventing and treating bone marrow proliferative tumors containing the antibody, wherein the antibody or the functional fragment thereof has an antigen recognition site for (a) a polypeptide chain consisting of an amino acid sequence shown in SEQ ID NO: 1, or (b) a polypeptide chain consisting of an amino acid sequence in which one or more amino acids are deleted, substituted or added in SEQ ID NO: 1.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a drug for diagnosing, preventing and treating bone marrow proliferative tumors. Background Art

[0002] In some patients with Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs), base deletions or insertions were found in exon 9 of the calreticulin (CALR) gene (Non-Patent Documents 1, 2). It has been found that the mutant CALR protein produced by the CALR mutant gene has the tumorigenicity to cause myeloproliferative neoplasms (MPNs) alone by constantly activating the thrombopoietin receptor (Non-Patent Documents 3 to 6).

[0003] The CALR gene mutation found in MPN patients is a frameshift mutation that is always localized in the final exon. The misalignment of the amino acid reading frame caused by the frameshift mutation is always +1. Therefore, there is a sequence at the carboxyl terminus of the mutant CALR protein that is not present in the wild type. In particular, the 44 amino acids at the carboxyl terminus are common to almost all mutant CALR proteins. As an example, Figure 1 , the carboxyl terminal sequences of the most frequent 52-base deletion (Del 52) and the second most frequent 5-base insertion (Ins 5) of CALR gene mutations found in MPN patients are compared with the corresponding regions of the wild-type CALR protein.

[0004] Since mutant CALR proteins that cause MPN are expressed in tumor cells, it has been suggested that sequences specific to mutant CALR proteins resulting from frameshift mutations could potentially serve as diagnostic markers or therapeutic targets as neoantigens (Patent Documents 1 to 2).

[0005] Prior art literature

[0006] Patent Literature

[0007] Patent Document 1: Japanese Patent Application No. 2016-537012

[0008] Patent Document 2: International Publication No. 2016 / 087514

[0009] Non-patent literature

[0010] 1:Klampfl T,Gisslinger H,Harutyunyan AS,et al.Somatic mutations of calreticulin in myeloproliferative neoplasms.The New Englandjournal of medicine.2013:369:2379-90.

[0011] Nonmutated JAK2:Nangalia J,Massie CE,Baxter EJ,et al.Somatic CALRmutations in myeloproliferative neoplasms with nonmutated JAK2.The NewEngland Journal of Medicine.2013:369:2391-405.

[0012] Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms.Blood.2016:127:1307-16.

[0013] Oncogenic Transformation 4:Elf S,Abdelfattah NS,Chen E,et al.Mutant CalreticulinRequires Both Its Mutant C-terminus and the Thrombopoietin Receptor forOncogenic Transformation.Cancer Discov.2016:6:368-81.

[0014] Novel 5:Marty C,Pecquet C,Nivarthi H,et al.Calreticulin mutant mice induce an MPL-dependent thrombocytosis with frequent progression of tomyelofibrosis.Blood.2016:127:1317-24.

[0015] Non-patent literature 6: Vainchenker W, Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood. 2017; 129: 667-79. Summary of the invention

[0016] Problems to be solved by the invention

[0017] However, it has been found that antibodies that recognize specific sequences (neoantigens) of mutant CALR proteins arising from the above-mentioned frameshift mutations cannot accurately detect mutant CALR proteins in cell extracts or on the cell surface.

[0018] Therefore, an object of the present invention is to provide a detection means for accurately detecting mutant CALR genes and proteins of MPN, a diagnosis, preventive or therapeutic drug for MPN, and a method for screening a therapeutic drug for MPN.

[0019] Methods for solving problems

[0020] The present inventors further repeated the functional analysis of mutant CALR proteins and found that most of the expressed mutant CALR proteins were in the specific sequence of the mutant protein ( Figure 1 ) is cleaved, and most of the sequence considered to be a neoantigen is lost. A mutant CALR protein is expressed in large quantities. Therefore, an antibody that specifically recognizes a very short amino acid sequence located on the amino-terminal side of the cleavage site in the neoantigen was prepared. As a result, the expression of the cleaved mutant CALR protein was confirmed not only in cultured cells but also in peripheral blood cells and platelets of patients. It was further clarified that when this antibody is used, the detection sensitivity of the mutant CALR protein on the cell surface is greatly improved, and an excellent MPN treatment effect can be obtained. It was thus clarified that in the diagnosis or treatment of MPN patients with CALR gene mutations, by detecting or targeting not only the full-length type (uncleaved type) but also the mutant CALR protein containing the cleaved type, a higher-performance pharmaceutical can be developed. In addition, it is strongly suggested that by inhibiting the cleavage of the mutant CALR protein, the effect of the pharmaceutical targeting the sequence lost due to the cleavage can be enhanced, and the present invention has been completed.

[0021] That is, the present invention provides the following [1] to

[14] .

[0022] [1] An antibody or a functional fragment thereof that binds to a truncated mutant CALR protein, which has an antigen recognition site for (a) a polypeptide chain consisting of the amino acid sequence shown in SEQ ID NO: 1, or (b) a polypeptide chain consisting of an amino acid sequence in which one or more amino acids are deleted, substituted or added in SEQ ID NO: 1.

[0023] [2] The antibody or functional fragment thereof that binds to the cleaved mutant CALR protein according to [1], which is selected from the following (c), (d) and (e).

[0024] (c) an antibody wherein CDR1, CDR2 and CDR3 of the immunoglobulin VH chain are respectively polypeptides consisting of the amino acid sequences set forth in SEQ ID NOs: 17, 18 and 19, or amino acid sequences in which one to several amino acids are deleted, substituted or added to the amino acid sequences set forth in SEQ ID NOs: 17, 18 and 19, and CDR1, CDR2 and CDR3 of the immunoglobulin VL chain are respectively polypeptides consisting of the amino acid sequences set forth in SEQ ID NOs: 26, 27 and 28, or amino acid sequences in which one to several amino acids are deleted, substituted or added to the amino acid sequences set forth in SEQ ID NOs: 26, 27 and 28;

[0025] (d) an antibody wherein CDR1, CDR2 and CDR3 of the immunoglobulin VH chain are respectively polypeptides consisting of the amino acid sequences set forth in SEQ ID NOs: 20, 21 and 22, or amino acid sequences in which one to several amino acids are deleted, substituted or added to the amino acid sequences set forth in SEQ ID NOs: 20, 21 and 22, and CDR1, CDR2 and CDR3 of the immunoglobulin VL chain are respectively polypeptides consisting of the amino acid sequences set forth in SEQ ID NOs: 29, 30 and 31, or amino acid sequences in which one to several amino acids are deleted, substituted or added to the amino acid sequences set forth in SEQ ID NOs: 29, 30 and 31;

[0026] (e) An antibody in which CDR1, CDR2 and CDR3 of the immunoglobulin VH chain are respectively polypeptides consisting of the amino acid sequences shown in SEQ ID NOs: 23, 24 and 25, or amino acid sequences in which 1 to several amino acids are deleted, substituted or added to the amino acid sequences shown in SEQ ID NOs: 23, 24 and 25, and CDR1, CDR2 and CDR3 of the immunoglobulin VL chain are respectively polypeptides consisting of the amino acid sequences shown in SEQ ID NOs: 32, 33 and 34, or amino acid sequences in which 1 to several amino acids are deleted, substituted or added to the amino acid sequences shown in SEQ ID NOs: 32, 33 and 34.

[0027] [3] The antibody or functional fragment thereof that binds to the cleaved mutant CALR protein according to [1] or [2], which is selected from the following (C), (D) and (E).

[0028] (C) an antibody having an immunoglobulin VH chain consisting of the amino acid sequence set forth in SEQ ID NO: 5, or an amino acid sequence in which 1 to several amino acids are deleted, substituted or added to the amino acid sequence set forth in SEQ ID NO: 5, and an immunoglobulin VL chain consisting of the amino acid sequence set forth in SEQ ID NO: 8, or an amino acid sequence in which 1 to several amino acids are deleted, substituted or added to the amino acid sequence set forth in SEQ ID NO: 8;

[0029] (D) an antibody having an immunoglobulin VH chain consisting of the amino acid sequence set forth in SEQ ID NO: 6, or an amino acid sequence in which 1 to several amino acids are deleted, substituted or added to the amino acid sequence set forth in SEQ ID NO: 6, and an immunoglobulin VL chain consisting of the amino acid sequence set forth in SEQ ID NO: 9, or an amino acid sequence in which 1 to several amino acids are deleted, substituted or added to the amino acid sequence set forth in SEQ ID NO: 9;

[0030] (E) An antibody having an immunoglobulin VH chain consisting of the amino acid sequence shown in SEQ ID NO: 7, or an amino acid sequence in which 1 to several amino acids are deleted, substituted or added to the amino acid sequence shown in SEQ ID NO: 7, and an immunoglobulin VL chain consisting of the amino acid sequence shown in SEQ ID NO: 10, or an amino acid sequence in which 1 to several amino acids are deleted, substituted or added to the amino acid sequence shown in SEQ ID NO: 10.

[0031] [4] An antibody or a functional fragment thereof that competes with the antibody of [2] or [3] in binding to the amino acid sequence portion of SEQ ID NO: 1 in a truncated mutant CALR protein.

[0032] [5] A pharmaceutical composition comprising the antibody or a functional fragment thereof according to any one of [1] to [4].

[0033] [6] The pharmaceutical composition according to [5], which is a diagnostic, preventive or therapeutic drug for bone marrow proliferative tumors.

[0034] [7] A method for detecting a mutant CALR protein associated with bone marrow proliferative tumors, characterized by detecting the following polypeptide (a) or (b) in a biological sample.

[0035] (a) a polypeptide consisting of the amino acid sequence shown in SEQ ID NO: 1;

[0036] (b) A polypeptide consisting of an amino acid sequence in which one or more amino acids are deleted, substituted or added in SEQ ID NO: 1.

[0037] [8] The method for detecting a mutant CALR protein according to [7], wherein the detection of the polypeptide of (a) or (b) is an immunological detection using the antibody or a functional fragment thereof according to any one of [1] to [4].

[0038] [9] A method for screening a drug for treating bone marrow proliferative tumors, characterized by screening a drug that binds to the following polypeptide (a) or (b).

[0039] (a) a polypeptide consisting of the amino acid sequence shown in SEQ ID NO: 1;

[0040] (b) A polypeptide consisting of an amino acid sequence in which one or more amino acids are deleted, substituted or added in SEQ ID NO: 1.

[0041]

[10] A method for diagnosing bone marrow proliferative tumors, characterized by detecting the following polypeptide (a) or (b) in a biological sample.

[0042] (a) a polypeptide consisting of the amino acid sequence shown in SEQ ID NO: 1;

[0043] (b) A polypeptide consisting of an amino acid sequence in which one or more amino acids are deleted, substituted or added in SEQ ID NO: 1.

[0044]

[11] The diagnostic method according to

[10] , wherein the detection of the polypeptide of (a) or (b) is an immunological detection using the antibody or a functional fragment thereof according to any one of [1] to [4].

[0045]

[12] A method for preventing or treating bone marrow proliferative tumors, characterized by administering the antibody or a functional fragment thereof according to any one of [1] to [4].

[0046]

[13] The antibody or functional fragment thereof according to any one of [1] to [4], which is used for the diagnosis of bone marrow proliferative tumors.

[0047]

[14] Use of the antibody or a functional fragment thereof according to any one of [1] to [4] for the manufacture of a diagnostic drug for bone marrow proliferative tumors.

[0048] Effects of the Invention

[0049] If an antibody having an antigen recognition site (epitope) for the polypeptide chain of (a) or (b) is used, the mutant CALR protein generated by the cleavage of the mutant CALR protein can be detected, and the detection sensitivity of the mutant CALR protein on the cell surface is greatly improved. Therefore, if the MPN diagnostic drug of the present invention is used, the detection sensitivity of MPN is greatly improved. In addition, if the antibody is used, MPN can be specifically prevented or treated. In addition, if a drug that binds to the polypeptides of (a) and (b) is screened, it is possible to screen for MPN therapeutic drugs. BRIEF DESCRIPTION OF THE DRAWINGS

[0050] Figure 1This is a diagram showing the characteristics of mutant CALR protein. The CALR gene mutation that causes bone marrow proliferative tumor patients is a +1 frameshift mutation, and the resulting mutant CALR protein has a common amino acid sequence in the mutant protein at the carboxyl terminus. SP: signal sequence, N: N domain, P: P domain. The arrow indicates the beginning of the amino acid sequence that is different from the wild type (WT).

[0051] Figure 2 This is a diagram showing antibodies that recognize sequences on the amino terminal side of a CALR protein and on the carboxyl terminal side of a mutant CALR protein. The antibody that recognizes the sequence on the amino terminal side of a CALR protein is a commercially available antibody (anti-CALR antibody) that recognizes an amino acid sequence that is closer to the amino terminal side than the mutation site of a mutant CALR protein. In addition, the antibody that recognizes a sequence on the carboxyl terminal side of a mutant CALR protein is a commercially available antibody (anti-mutant CALR antibody) that recognizes an amino acid sequence that is newly formed by a mutation in a base sequence on the carboxyl terminal side of a CALR protein.

[0052] Figure 3 This indicates the use of proteins secreted by UT-7 / TPO cells (Komatsu N. et al., Blood, 1996, 87, 4552-4556). Figure 2 The figure shows the results of immunoblotting analysis using antibodies. Since vec is a cell into which only the expression vector has been introduced, endogenous CALR protein is detected in the same manner as UT-7 / TPO cells / CALR (WT). In Del 52 and Ins 5 types, mutant CALR proteins with a smaller molecular weight than the full-length mutant CALR protein detected using the anti-mutant CALR antibody can be detected using only the anti-CALR antibody (asterisk in the figure). In addition, in Ins 5 type, since the full-length mutant CALR protein is migrated to almost the same position as the endogenous wild-type CALR protein, it cannot be specifically detected using the anti-CALR antibody.

[0053] Figure 4 Schematic diagram showing proteins with FLAG tags fused to the amino (N) terminus and carboxyl (C) terminus of representative mutant CALR proteins, Del 52 and Ins 5. The mutant-specific sequence is indicated in black, and the FLAG tag is indicated by diagonal lines.

[0054] Figure 5This is a diagram showing the results of measuring the amount of mutant CALR protein on the cell surface by flow cytometry analysis using an anti-FLAG antibody. Regardless of the presence or absence of cleavage, a stronger signal was detected in cells expressing mutant CALR protein with a FLAG tag at the N-terminus with the tag remaining, compared to cells in which the C-terminal FLAG was cleaved due to cleavage in a sequence specific to the mutant CALR protein. In addition, a difference was observed that the expression level of the Del 52 type was lower than that of the Ins 5 type.

[0055] Figure 6 The diagram shows an antibody that recognizes a mutant-specific sequence located on the amino-terminal side of the cleavage site of the protein generated within the mutant CALR protein-specific sequence (black).

[0056] Figure 7 Indicates the use Figure 6 Antibody pairs Figure 3 The results of flow cytometry analysis of the cells used in the experiment. The difference in the amount of detection due to the position of the FLAG tag was eliminated. In addition, the difference that the expression level of Del 52 type was lower than that of Ins 5 type was observed.

[0057] Figure 8 This is a diagram showing the detection of truncated CALR protein in myeloid proliferative tumor patient cells. Cell extracts prepared from patient cells were analyzed by immunoblotting using an antibody that recognizes an amino acid sequence located at the amino terminal side of the cleavage site of the protein produced within a sequence specific to the mutant CALR protein. Expression of truncated mutant CALR protein that can be recognized by the antibody was detected in peripheral blood mononuclear cells or platelets of myeloid proliferative tumor patients with CALR gene mutations.

[0058] Fig. 9 This is a diagram showing that clone B3, C6, and G1 antibodies all recognize mutant CALR proteins of both full-length and truncated forms. This is a diagram showing the results of immunoblotting analysis of proteins secreted from UT-7 / TPO cells using clone B3 antibodies and clone C6 and G1 antibodies. As with the anti-FLAG antibody, even if any of the B3, C6, and G1 antibodies is used, both the full-length Del 52 and Ins 5 types, in which a FLAG tag is added downstream of the signal sequence at the amino terminal, and the truncated forms with lower molecular weight can be detected.

[0059] Fig.10This is a diagram showing that clone B3, C6, and G1 antibodies all recognize mutant CALR proteins on the cell surface. This is a diagram showing the results of flow cytometry analysis of UT-7 / TPO cells expressing mutant CALR proteins of type Del 52 or type Ins 5 with FLAG tags added, and UT-7 / TPO / vec cells into which only the expression vector was introduced, using clone B3 antibodies and clone C6 and G1 antibodies to measure the amount of mutant CALR proteins on the cell surface. In addition, since the expression level of type Del 52 is lower than that of type Ins 5, the difference in signal intensity due to the type of mutation can be seen.

[0060] Fig.11 This is a graph showing the evaluation results of the binding ability of clone B3, C6, and G1 antibodies to mutant CALR proteins. The binding specificity to Del 52 mutant CALR proteins was evaluated by ELISA using clone B3 antibodies, clone C6 and G1 antibodies, and control rat IgG. All clone B3, C6, and G1 antibodies detected specific binding to mutant CALR proteins in a concentration-dependent manner.

[0061] Fig.12 This is a graph showing the results of evaluating the binding strength of the clone B3 antibody to the antigen used for antibody production by surface plasmon resonance analysis. The binding strength of the clone B3 antibody to the antigen used for antibody production was evaluated by surface plasmon resonance analysis.

[0062] Fig.13A This is a diagram showing the results of identifying the antigen recognition sequences of clone B3, C6, and G1 antibodies by immunoblotting. Proteins in which the amino acids described in the figure are substituted with alanine (A) in the mutant CALR protein of the Del 52 type are expressed, and the reactivity of each antibody is evaluated by immunoblotting. Original (Intact) represents the mutant CALR protein of the Del 52 type without amino acid substitution. The amino acids surrounded by the thick black line represent the antigen sequence used in the preparation of the antibody.

[0063] Fig. 13B The figure shows the results of identifying the antigen recognition sequences of clones B3, C6, and G1 antibodies by ELISA. Fig.13A Reactivity of the same protein. Original (Intact) indicates a mutant CALR protein of the Del 52 type without amino acid substitution. The amino acids enclosed by a thick black line indicate the antigen sequence used in the preparation of the antibody.

[0064] Fig.14 It is a diagram showing the amino acid sequence of the heavy chain variable region of the antibody of the present invention (B3, C6, G1).

[0065] Fig.15 It is a diagram showing the amino acid sequence of the light chain variable region of the antibody of the present invention (B3, C6, G1).

[0066] Fig.16 It is a diagram showing the base sequences of the heavy chain variable regions of the antibodies of the present invention (B3, C6, G1).

[0067] Fig.17 It is a diagram showing the base sequences of the light chain variable regions of the antibodies of the present invention (B3, C6, G1).

[0068] Fig.18 This is a graph showing the therapeutic effect of B3 mouse chimeric antibody on MPN model mice. B3 chimeric antibody or solvent (PBS) was administered weekly from the 9th week after transplantation to osteoblastic tumor model mice (CALR Del 52 mice) produced by transplanting hematopoietic stem cells expressing Del 52 mutant CALR protein and control mice produced by transplanting or introducing hematopoietic stem cells with a control vector, and the inhibitory effect on thrombocytosis characteristic of osteoblastic tumor model mice was evaluated. DETAILED DESCRIPTION

[0069] The polypeptides of (a) or (b) used as targets for the methods of detecting and diagnosing mutant CALR proteins associated with MPN and the prevention or treatment of MPN of the present invention are polypeptides having specific sequences (corresponding to Figure 1 The polypeptide is a polypeptide remaining at the carboxyl terminal side after being cut from the 44 amino acids common to the mutant CALR proteins in .

[0070] The wild-type CALR protein has Figure 1 The amino acid sequence shown is (SEQ ID NO: 2). In addition, the 52-base deletion type (Del 52) with the highest frequency among CALR gene mutations has Figure 1 The amino acid sequence shown in (SEQ ID NO: 3). In addition, among CALR gene mutations, the second most frequent 5-base insertion type (Ins 5) has Figure 1 The amino acid sequence shown (SEQ ID NO: 4). Figure 1 The region surrounded by a box in the figure is a common amino acid sequence in mutant CALR proteins. The truncated mutant CALR protein contains only 13 amino acids on the amino terminal side of the common region. The present inventors have discovered for the first time that when the common region is truncated to produce a truncated mutant CALR protein, most of the common region is lost from the mutant CALR protein.

[0071] The polypeptide (a) is composed of the amino acid sequence shown in sequence number 1. As the amino acid sequence in which one or several amino acids are deleted, substituted or added in the polypeptide (b), the amino acid sequence in which 1 to 4 amino acids are deleted, substituted or added in sequence number 1 is preferred, and the amino acid sequence in which 1 to 3 amino acids are deleted, substituted or added is more preferred. More specifically, the amino acid sequence in which 3 amino acids are deleted from the carboxyl terminal side of sequence number 1 is more preferred. In addition, the identity between the amino acid sequence of polypeptide (b) and the amino acid sequence of sequence number 1 is preferably 80% or more, more preferably 85% or more, and further preferably 90% or more.

[0072] In the method for detecting a mutant CALR protein associated with MPN and the method for diagnosing, preventing, and treating MPN of the present invention, an antibody or a functional fragment thereof that binds to the polypeptide of (a) or (b) in a biological sample is used.

[0073] The above-mentioned antibody may be any antibody as long as it has an antigen recognition site (epitope) for the polypeptide chain of (a) or (b), and may be an antibody that binds only to the truncated mutant CALR protein, or may be an antibody that binds to both the truncated mutant CALR protein and the full-length mutant CALR protein, preferably an antibody specific for the "mutant CALR protein" that binds to both the truncated mutant CALR protein and the full-length mutant CALR protein. Specific examples include antibodies selected from the following (c), (d), and (e).

[0074] (c) An antibody in which the CDR1, CDR2 and CDR3 of the immunoglobulin VH chain are respectively polypeptides consisting of the amino acid sequences shown in SEQ ID NOs: 17, 18 and 19, or amino acid sequences in which 1 to several amino acids are deleted, substituted or added to the amino acid sequences shown in SEQ ID NOs: 17, 18 and 19, and the CDR1, CDR2 and CDR3 of the immunoglobulin VL chain are respectively polypeptides consisting of the amino acid sequences shown in SEQ ID NOs: 26, 27 and 28, or amino acid sequences in which 1 to several amino acids are deleted, substituted or added to the amino acid sequences shown in SEQ ID NOs: 26, 27 and 28.

[0075] (d) An antibody in which the CDR1, CDR2 and CDR3 of the immunoglobulin VH chain are respectively polypeptides consisting of the amino acid sequences shown in SEQ ID NOs: 20, 21 and 22, or amino acid sequences in which 1 to several amino acids are deleted, substituted or added to the amino acid sequences shown in SEQ ID NOs: 20, 21 and 22, and the CDR1, CDR2 and CDR3 of the immunoglobulin VL chain are respectively polypeptides consisting of the amino acid sequences shown in SEQ ID NOs: 29, 30 and 31, or amino acid sequences in which 1 to several amino acids are deleted, substituted or added to the amino acid sequences shown in SEQ ID NOs: 29, 30 and 31.

[0076] (e) An antibody in which CDR1, CDR2 and CDR3 of the immunoglobulin VH chain are respectively polypeptides consisting of the amino acid sequences shown in SEQ ID NOs: 23, 24 and 25, or amino acid sequences in which 1 to several amino acids are deleted, substituted or added to the amino acid sequences shown in SEQ ID NOs: 23, 24 and 25, and CDR1, CDR2 and CDR3 of the immunoglobulin VL chain are respectively polypeptides consisting of the amino acid sequences shown in SEQ ID NOs: 32, 33 and 34, or amino acid sequences in which 1 to several amino acids are deleted, substituted or added to the amino acid sequences shown in SEQ ID NOs: 32, 33 and 34.

[0077] As the amino acid sequence in which one to several amino acids are deleted, substituted or added in the amino acid sequence shown in the above-mentioned sequence numbers 17 to 34, the amino acid sequence in which 1 to 4 amino acids are deleted, substituted or added in the sequence numbers 17 to 34 is preferred, the amino acid sequence in which 1 to 3 amino acids are deleted, substituted or added is more preferred, and the amino acid sequence in which 1 to 2 amino acids are deleted, substituted or added is further preferred. In addition, the identity between the amino acid sequence shown in the sequence numbers 17 to 34 and the amino acid sequence in which one to several amino acids are deleted, substituted or added is preferably 80% or more, more preferably 85% or more, and further preferably 90% or more.

[0078] As an antibody having an antigen recognition site (epitope) for the polypeptide chain of (a) or (b) above, an antibody selected from the following (C), (D) and (E) is more preferred.

[0079] (C) An antibody having an immunoglobulin VH chain consisting of the amino acid sequence shown in SEQ ID NO: 5, or an amino acid sequence in which 1 to several amino acids are deleted, substituted or added to the amino acid sequence shown in SEQ ID NO: 5, and an immunoglobulin VL chain consisting of the amino acid sequence shown in SEQ ID NO: 8, or an amino acid sequence in which 1 to several amino acids are deleted, substituted or added to the amino acid sequence shown in SEQ ID NO: 8.

[0080] (D) An antibody having an immunoglobulin VH chain consisting of the amino acid sequence shown in SEQ ID NO: 6, or an amino acid sequence in which 1 to several amino acids are deleted, substituted or added to the amino acid sequence shown in SEQ ID NO: 6, and an immunoglobulin VL chain consisting of the amino acid sequence shown in SEQ ID NO: 9, or an amino acid sequence in which 1 to several amino acids are deleted, substituted or added to the amino acid sequence shown in SEQ ID NO: 9.

[0081] (E) An antibody having an immunoglobulin VH chain consisting of the amino acid sequence shown in SEQ ID NO: 7, or an amino acid sequence in which 1 to several amino acids are deleted, substituted or added to the amino acid sequence shown in SEQ ID NO: 7, and an immunoglobulin VL chain consisting of the amino acid sequence shown in SEQ ID NO: 10, or an amino acid sequence in which 1 to several amino acids are deleted, substituted or added to the amino acid sequence shown in SEQ ID NO: 10.

[0082] As the amino acid sequence in which one to several amino acids are deleted, substituted or added in the amino acid sequence shown in the above-mentioned sequence numbers 5 to 10, the amino acid sequence in which 1 to 10 amino acids are deleted, substituted or added in the amino acid sequence shown in the above-mentioned sequence numbers 5 to 10 is preferred, the amino acid sequence in which 1 to 8 amino acids are deleted, substituted or added in the amino acid sequence shown in the above-mentioned sequence numbers 5 to 10 is more preferred, and the amino acid sequence in which 1 to 5 amino acids are deleted, substituted or added in the amino acid sequence shown in the above-mentioned sequence numbers 5 to 10 is more preferred. The identity between the amino acid sequence shown in the above-mentioned sequence numbers 5 to 10 and the amino acid sequence in which one to several amino acids are deleted, substituted or added in the amino acid sequence shown in the above-mentioned sequence numbers 5 to 10 is preferably 80% or more, more preferably 85% or more, and even more preferably 90% or more.

[0083] The antibody of the present invention has the sequence of each CDR of (c) to (e) above, or the sequence of the immunoglobulin VH region and VL region of (C) to (E), and the amino acid sequence of the region outside these regions is not particularly limited. Therefore, the antibody of the present invention can be a mammal antibody other than rat, such as a human antibody, or a humanized antibody. More specifically, it can be a chimeric antibody composed of the variable regions of the heavy chain and light chain of a mammal other than human, such as a rat antibody, and the constant regions of the heavy chain and light chain of a human antibody. Such an antibody can be obtained by linking the DNA encoding the variable region of the rat antibody to the DNA encoding the constant region of the human antibody, inserting it into an expression vector, and introducing it into a host and producing it. Humanized antibodies are also called reshaped human antibodies, which are antibodies obtained by transplanting the CDR of a mammal other than human, such as a rat antibody, into the CDR of a human antibody, and their usual genetic recombination methods are also known. As a specific example, a DNA sequence designed to link the CDR of a rat antibody to the framework region (FR) of a human antibody is synthesized by PCR from several oligonucleotides made in a manner having an overlap at the end. The obtained DNA is linked to the DNA encoding the constant region of a human antibody, then inserted into an expression vector, introduced into a host and produced (see European Patent Application Publication No. EP239400, International Patent Application Publication No. WO96 / 02576). The FR of a human antibody linked via CDR can select an antibody whose CDR forms a good antigen binding site. As needed, the amino acids of the FR of the variable region of the antibody can be replaced in a manner such that the CDR of a reconstructed human antibody forms an appropriate antigen binding site (Sato, K. et al., Cancer Res, 1993, 53, 851-856.).

[0084] In addition, methods for obtaining human antibodies are also known. For example, human lymphocytes can be sensitized in vitro with cells expressing a desired antigen or a desired antigen, and sensitized lymphocytes are fused with human myeloma cells, such as U266, to obtain a desired human antibody with binding activity to an antigen (refer to Japanese Patent Publication No. 1-59878). In addition, transgenic animals with a repertoire of human antibody genes can be immunized with a desired antigen to obtain a desired human antibody (refer to WO93 / 12227, WO92 / 03918, WO94 / 02602, WO94 / 25585, WO96 / 34096, WO96 / 33735). In addition, it is also known to use a human antibody library and obtain a human antibody by screening. For example, the variable region of a human antibody can be expressed on the surface of a phage as a single-chain antibody (scFv) using a phage display method, and a phage that binds to an antigen is selected. If the gene of the selected phage is analyzed, the DNA sequence encoding the variable region of the human antibody that binds to the antigen can be determined. If the DNA sequence of the scFv that binds to the antigen is clear, an appropriate expression vector can be prepared for the sequence to obtain the human antibody. These methods are already known, and reference can be made to WO92 / 01047, WO92 / 20791, WO93 / 06213, WO93 / 11236, WO93 / 19172, WO95 / 01438, and WO95 / 15388.

[0085] The type of the antibody is not particularly limited, and includes antibodies having any isotype such as IgG, IgM, IgA, IgD, or IgE. In consideration of ease of purification, IgG is preferred.

[0086] Examples of functional fragments include low-molecular-weight antibodies such as antibody fragments (fragments) or modified antibodies. Specific examples of antibody fragments include Fab, Fab', F(ab')2, Fv, scFv, and Diabody.

[0087] In addition, among the antibodies of the present invention, the antibodies used for detecting the polypeptides of (a) or (b) above may be antibodies that bind to these polypeptides. On the other hand, the antibodies used for preventing or treating MPN are preferably antibodies that bind to the polypeptides of (a) or (b) above and have cell-killing activity.

[0088] An antibody that binds to a truncated mutant CALR protein may be any antibody that binds to a polypeptide chain having the sequence shown in SEQ ID NO: 1, and preferably an antibody that competes with at least one of the above antibodies or functional fragments thereof in binding to the amino acid sequence portion shown in SEQ ID NO: 1 in the truncated mutant CALR protein.

[0089] Here, examples of biological samples used for the above-mentioned detection include biological samples collected from subjects and containing the polypeptides of (a) or (b). Specifically, examples include body fluids such as whole blood, plasma, serum, lymphocytes, lymph fluid, platelets, monocytes, granulocytes, saliva or urine, and tissue specimens (bone marrow fluid, bone marrow tissue) obtained by bone marrow biopsy.

[0090] Means for detecting the polypeptide of (a) or (b) include liquid chromatography mass spectrometry, immunological methods, methods using low / medium molecules, nucleic acids or nucleic acid derivatives having specific binding ability, etc., and immunological methods that are simple and have high measurement sensitivity are preferred.

[0091] As an immunological method, an immunological method using an antibody or a functional fragment thereof having an antigen recognition site (epitope) for the polypeptide chain of (a) or (b) is preferred. As an epitope in the polypeptide chain of (a) or (b), any sequence present in the polypeptide chain of (a) or (b) is sufficient, preferably a peptide having more than three consecutive amino acids in the polypeptide chain of (a) or (b), and more preferably a peptide having more than five consecutive amino acids in the polypeptide chain of (a) or (b).

[0092] The antibody used in the immunological method can be, for example, an antibody obtained by using a peptide having three or more consecutive amino acids in the polypeptide chain of (a) or (b) as an antigen, and can be a polyclonal antibody or a monoclonal antibody, preferably a monoclonal antibody. Here, the monoclonal antibody can be produced as follows: for example, antibody-producing cells obtained by sensitizing a peptide having three or more consecutive amino acids in the polypeptide chain of (a) or (b) are fused with osteomyeloma cells to produce hybridomas, clones producing the target antibody are selected, and the cells are proliferated.

[0093] As an immunological method, any of immunochromatography, enzyme-labeled immunoassay (EIA), radioimmunoassay (RIA), agglutination, turbidimetry, flow cytometry, tissue immunostaining, immunoblotting, and the like can be used. Here, immunoblotting is a method of transferring a polypeptide to a membrane and detecting the polypeptide on the membrane with an antibody. Enzyme labeling, fluorescent labeling, and the like can be used for antibody detection.

[0094] If the polypeptide (a) or (b) is detected in a biological sample, the biological sample can be determined to be derived from a patient with a bone marrow proliferative tumor.

[0095] The MPN diagnostic drug of the present invention comprises an antibody having an antigen recognition portion (epitope) for the polypeptide chain of (a) or (b) above. The antibody is preferably the above-mentioned antibody.

[0096] Furthermore, the MPN diagnostic drug of the present invention may contain a buffer, instructions for performing the measurement, and the like in addition to the above-mentioned antibody.

[0097] The pharmaceutical composition such as the MPN preventive or therapeutic drug of the present invention may contain the above-mentioned antibody and can be prepared by mixing, dissolving, emulsifying, encapsulating, lyophilizing, etc. with a pharmaceutically acceptable carrier.

[0098] The MPN to be prevented or treated by the pharmaceutical composition of the present invention is preferably an MPN in which mutant CALR is detected.

[0099] Preferred preparations for oral administration are liquid preparations obtained by dissolving an effective amount of the antibody of the present invention in a diluent such as water or physiological saline; capsules, granules, powders or tablets containing an effective amount in a solid or granular form; liquid suspensions in which an effective amount is suspended in an appropriate dispersion medium; emulsions obtained by dispersing a solution in which an effective amount is dissolved in an appropriate dispersion medium and emulsifying the solution, etc.

[0100] When used for non-oral administration, the antibody of the present invention can be formulated together with pharmaceutically acceptable solvents, excipients, binders, stabilizers, dispersants, etc. into dosage forms such as injection solutions, suspensions, emulsions, creams, ointments, inhalants, suppositories, etc. In the injection formulation, the antibody of the present invention can be dissolved in an aqueous solution, preferably a physiologically appropriate buffer such as Hanks solution, Ringer's solution, or saline buffer. In addition, the medicine of the present invention can be formed into a suspension, solution, or emulsion in an oily or aqueous medium. Alternatively, the antibody of the present invention can be manufactured in the form of a powder, and an aqueous solution or suspension can be prepared using sterile water, etc. before use. When used for administration by inhalation, the antibody of the present invention can be powdered and prepared into a powder mixture with an appropriate base such as lactose or starch. Suppository formulations can be prepared by mixing the antibody of the present invention with a conventional suppository base such as cocoa butter. In addition, the therapeutic agent of the present invention can be enclosed in a polymer matrix, etc., and formulated as a sustained release preparation.

[0101] The screening method for the MPN therapeutic drug of the present invention is characterized in that the antibody or protein, low / medium molecule, nucleic acid or nucleic acid derivative that recognizes the polypeptide of (a) or (b) above is screened. Specifically, the development of antibody drugs with antibody-dependent cellular killing activity or complement-dependent cellular killing activity using antibodies that recognize the polypeptide of (a) or (b) can be cited. The above-mentioned antibody of the present invention is an example of an antibody drug obtained by the screening method of the present invention. In addition, the development of anti-tumor drugs that specifically deliver low or medium molecule compounds, nucleic acids or nucleic acid derivatives, proteins, etc. that specifically bind to the polypeptide of (a) or (b) can be cited.

[0102] Example

[0103] The present invention will be described in further detail below with reference to examples, but the present invention is not limited to these examples.

[0104] [Test Example 1]

[0105] (1) Materials and test methods

[0106] [1] Anti-CALR antibodies

[0107] Rabbit monoclonal antibody clone D3E6 (Cat#12238) manufactured by Cell Signaling Technology

[0108] [2] Anti-mutant CALR antibodies

[0109] Mouse monoclonal antibody clone CAL2 (Cat#DIA-CAL) manufactured by Dianova

[0110] [3] Antibodies that recognize mutant CALR proteins located on the amino-terminal side of the cleavage site

[0111] A peptide having cysteine ​​added to the carboxyl or amino terminus of the amino acid sequence (RRMMRTKMR) contained in sequence number 1 was synthesized, and after binding to the carrier protein keyhole limpet hemocyanin (KLH), 8-week-old female WKY / Izm rats were immunized, and lymphocytes were collected after additional immunization. Lymphocytes were fused with mouse myeloma SP2 cells by the PEG method, and then cultured in a selective medium to obtain hybridomas. The specificity of antibodies in the culture supernatant was screened by the ELISA method using the immunized peptide or purified protein, thereby obtaining hybridomas (clones B3, C6, and G1) that produce antibodies that bind to mutant CALR proteins containing truncated forms. The antibodies produced from these hybridomas were purified and used in the test (B3 antibody, C6 antibody, and G1 antibody).

[0112] [4] Test methods

[0113] UT-7 / TPO / CALR Del52 and UT-7 / TPO / CALR Ins 5 cells, which were tumor-growing cells by expressing Del 52 or Ins5 mutant CALR proteins in the human megakaryoblastic leukemia cell line UT-7 / TPO, as well as UT-7 / TPO / CALR (WT) cells expressing wild-type CALR as a control, and UT-7 / TPO / vec cells into which only the vector used for gene transfer was introduced were incubated at 6.0×105 The cells were seeded at a density of 100 cells / mL in OptiMEM medium (Thermo Fisher Company Cat#31985070) and cultured at 37°C for 32 hours in the presence of 5% CO2. At this time, UT-7 / TPO / CALRWT and UT-7 / TPO / vec cells were cultured in a medium containing 10 ng / mL thrombopoietin (TPO). The cells were removed by centrifugation (15,000 g × 10 minutes, 4°C), and the culture supernatant was obtained from the culture medium. The obtained fractions were heat-treated in the presence of a reducing agent, developed on a gel by SDS polyacrylamide electrophoresis, and electroblotted onto a polyvinylidene fluoride (PVDF) membrane. After reacting with a TBS-T solution (0.1% Tween-20, 150 mM sodium chloride, 50 mM Tris-HCl, pH 7.5) containing 5% skim milk at room temperature for 1 hour, the membrane was reacted with a 5% BSA / TBS-T solution containing an antibody that recognizes both the wild type and mutant types (rabbit monoclonal antibody D3E6, Cell Signaling Company Cat#12238) or a commercially available antibody that recognizes the carboxyl terminal sequence of the mutant type (mouse monoclonal antibody CAL2, Dianova Company Cat#DIA-CAL-250) at 4°C overnight. After washing with TBS-T solution, the membrane was reacted at room temperature for 1 hour in 5% skim milk / TBS-T solution containing peroxidase-labeled anti-rabbit IgG antibody (Cat#sc-2030, Santa Cruz) or peroxidase-labeled anti-mouse IgG antibody (Cat#sc-2005, Santa Cruz). After washing the PVDF membrane with TBS-T solution, the signal obtained by reacting with peroxidase luminescent reagent (Cat#34094, Thermo Fisher Scientific) was detected using FUSION camera (Vilber-Lourmat).

[0114] A mutant CALR protein of the Del 52 type in which a histidine tag was inserted downstream of the signal sequence at the amino terminal was expressed in HEK293T cells, and a culture supernatant containing the secreted mutant CALR protein was prepared by centrifugation (15,000 g × 10 minutes, 4°C). The obtained supernatant was applied to a HisTrap column (GE Healthcare Cat#17531901), and the column was washed with a purification buffer (0.3 M sodium chloride, 25 mM Tris-HCl, pH 7.4) containing 20 mM imidazole, and then the mutant CALR protein was purified using a purification buffer containing 50 mM imidazole. The purified protein was reacted with 2-nitro-5-thiocyanobenzoic acid (NTCB) to cyanate the cysteine ​​residues, and then fragmented under alkaline conditions. The masses of the protein fragments were then identified using a matrix-assisted laser desorption ionization time-of-flight mass spectrometer, and the cleavage site was determined based on the peptide sequence information of the Del 52 mutant CALR protein.

[0115] The mutant CALR protein of Del 52 type or Ins 5 type tagged with FLAG tag downstream of the signal sequence at the amino terminal or tagged with FLAG tag at the carboxyl terminal was expressed in UT-7 / TPO cells and cultured in Iscove's Modified Dulbecco's (IMDM) medium containing 10% fetal bovine inactivated serum at 37°C in the presence of 5% CO2. 5After washing with PBS (phosphate buffer containing 137 mM sodium chloride and 27 mM potassium chloride), the cells were reacted with mouse anti-DYKDDDDK tag antibody (Fujifilm Wako Pure Chemical Industries, Ltd. Cat#014-22383) or rat anti-mutant CALR antibody on the amino-terminal side of the cleavage site in 2% FBS / PBS solution on ice for 30 minutes. After the reaction, the cells were washed with 2% FBS / PBS solution, and then, as secondary antibodies, anti-mouse IgG-Alexa Fluor 647 (Thermo Fisher Scientific, Inc. Cat#A21235) and anti-rat IgG-Alexa Fluor 647 (ThermoFisher Scientific, Inc. Cat#A21247) were reacted in 2% FBS / PBS solution on ice for 30 minutes. After the reaction, the cells were collected by centrifugation and reacted with PBS solution containing 2% paraformaldehyde on ice for 15 minutes. Finally, after adding 2% FBS / PBS solution, centrifugation was performed (400 g×5 minutes, 4° C.), and the supernatant was discarded to wash the cells. 300 μL of 2% FBS / PBS solution was added, and the signal was quantified by flow cytometry analysis using FACS Calibur (BD biosciences).

[0116] Regarding human peripheral blood mononuclear cells, peripheral blood collected in a conical tube containing an anticoagulant was centrifuged (500 g × 10 minutes, 4°C) to obtain a cell fraction, which was suspended in a PBS solution and then placed on a lymphocyte separation solution Lymphosep (MP biomedicals Cat#11444815), and a buffy coat was obtained by centrifugation (1500 rpm × 30 minutes, room temperature). PBS solution was added to the obtained buffy coat, and after resuspending, centrifugation (1500 rpm × 10 minutes, room temperature) was performed, and peripheral blood mononuclear cells were obtained by removing the supernatant. The obtained cells were suspended in RIPA solution (150 mM sodium chloride, 1 mM EDTA, 1% NP-40, 1% sodium deoxycholate, 2 mM sodium orthovanadate (V), 10 Mm β-glycerophosphate, 1 μg / mL aprotinin, 2 μg / mL E-64, 1 μg / mL leupeptin, 0.67 μg / mL ubenimex, 0.67 μg / mL pepstatin, 43.5 μg / mL PMSF, 20 mM Tris-HCl, pH 7.4), and then ultrasonically disrupted and centrifuged (15000 g × 15 min, 4°C), and the supernatant was recovered to prepare a cell extract. After the obtained cell extract was heat-treated in the presence of a reducing agent, it was developed on a gel using SDS polyacrylamide electrophoresis, electroblotted onto a polyvinylidene fluoride (PVDF) membrane, reacted with a TBS-T solution containing 5% skim milk for 1 hour at room temperature, and then reacted with a 5% BSA / TBS-T solution containing a rat anti-mutant CALR antibody that recognizes the amino-terminal side of the cleavage site at 4°C overnight. After washing with a TBS-T solution, it was reacted in a 5% skim milk / TBS-T solution containing a peroxidase-labeled anti-rat IgG antibody (Santa Cruz Cat#sc-2006) at room temperature for 1 hour. After washing the PVDF membrane with a TBS-T solution, the signal obtained by reacting with the peroxidase luminescent reagent was detected using a FUSION camera.

[0117] Regarding platelets, peripheral blood collected in a conical tube containing EDTA was centrifuged (500 g × 10 minutes, 4°C) to obtain a supernatant, and the precipitate obtained by centrifuging the supernatant (2000 × g, 15 minutes, 4°C) was washed twice with 500 μL of a platelet washing solution (10 mM sodium citrate, 150 mM sodium chloride, 1 mM EDTA, 1% dextrose, pH 7.4). The obtained platelets were suspended in a RIPA solution, ultrasonically disrupted, and then centrifuged (15000 g × 15 minutes, 4°C) to recover the supernatant to prepare a cell extract. After the obtained cell extract was heat-treated in the presence of a reducing agent, it was developed on a gel using SDS polyacrylamide electrophoresis, electroblotted onto a polyvinylidene fluoride (PVDF) membrane, reacted with a TBS-T solution containing 5% skim milk for 1 hour at room temperature, and then reacted with a 5% BSA / TBS-T solution containing a rat anti-mutant CALR antibody (B3 antibody) that recognizes the amino-terminal side of the cleavage site at 4°C overnight. After washing with a TBS-T solution, it was reacted with a 5% skim milk / TBS-T solution containing a peroxidase-labeled anti-rat IgG antibody (Santa Cruz Cat#sc-2006) at room temperature for 1 hour. After washing the PVDF membrane with a TBS-T solution, the signal obtained by reacting with the peroxidase luminescent reagent was detected using a FUSION camera.

[0118] (2) Results

[0119] CALR protein contained in the culture supernatant of UT-7 / TPO / CALR Del52 and UT-7 / TPO / CALRIns 5 cells, which are tumor-growing cells expressing Del 52 or Ins 5 mutant CALR proteins in the human megakaryoblastic leukemia cell line UT-7 / TPO, as well as UT-7 / TPO / CALR (WT) expressing wild-type CALR as a control, and UT-7 / TPO / vec introduced with only the vector used for gene introduction, was evaluated using an antibody that recognizes both the wild-type and mutant types (monoclonal antibody D3E6, Cell Signaling Cat#12238) and a commercially available antibody that recognizes the carboxyl terminal sequence of the mutant type (monoclonal antibody CAL2, Dianova Cat#DIA-CAL-250) ( Figure 2 As a result, in immunoblotting using an antibody that recognizes wild-type and mutant CALR proteins (B3 antibody), cells expressing mutant CALR protein detected a band that could not be recognized by the mutant antibody in addition to endogenous CALR ( Figure 3 ).

[0120] Among the peptide fragments fragmented at the amino terminal side of the cysteine ​​residue using NTCB, the molecular weights of the peptide fragments found only in the cleavage form of the mutant CALR protein (using the Del 52 type) were 25827.7 and 25418.4. By comparing this value with the estimated molecular weight determined from the position of the cysteine ​​residue obtained by cleavage, the cleavage sites of the Del52 type mutant CALR protein were identified as between the 380th methionine residue and the 381st arginine residue, and between the 377th methionine residue and the 378th arginine residue.

[0121] Del 52 type or Ins 5 type mutant CALR proteins tagged with FLAG tag downstream of the signal sequence at the amino terminal or tagged with FLAG tag at the carboxyl terminal were expressed in UT-7 / TPO cells. When flow cytometry analysis was performed using an anti-FLAG antibody regarding the expression of mutant CALR proteins on the cell surface, cells expressing mutant CALR proteins with FLAG tag at the amino terminal gave stronger signals than cells expressing mutant CALR proteins tagged with FLAG tag at the carboxyl terminal ( Figure 4 , 5 Next, the antibody obtained by immunization with a peptide containing a sequence specific to the mutant CALR protein on the amino-terminal side of the cleavage site was used to perform Figure 4 , 5 When analyzing the cell lines used in the analysis by flow cytometry, the difference in the amount of detection caused by the location of the FLAG tag addition disappeared ( Figure 6 , 7 ) This indicates that setting an antigen recognition site on the carboxyl terminal side that remains after being cleaved in the sequence specific to the mutant CALR protein is important for creating a more sensitive test reagent or a more potent therapeutic drug.

[0122] In fact, using an antibody specific to mutant CALR located on the amino-terminal side of the cleavage site, cell extracts of peripheral blood mononuclear cells or platelets obtained from patients with positive CALR gene mutations were analyzed by immunoblotting. As a result, expression of the cleaved mutant CALR protein was confirmed in the same manner as in the case of the cell line ( Figure 8 ). This shows that the same cleavage actually occurs even in patient cells, and that setting an antigen recognition site on the carboxyl terminal side that remains after cleavage is important for creating a more sensitive test reagent or a more potent therapeutic drug.

[0123] [Test Example 2]

[0124] (1) Confirmation that the three antibodies recognize the full-length and truncated mutant CALR proteins

[0125] UT-7 / TPO cells expressing mutant CALR proteins of the Del 52 type or Ins 5 type with a FLAG tag inserted downstream of the signal sequence at the amino terminal were cultured, and the culture supernatant containing the secreted mutant CALR protein was prepared by centrifugation (1,600 g × 5 minutes, 4°C). The obtained culture supernatant was heat-treated in the presence of SDS and a reducing agent, developed on a gel by SDS polyacrylamide electrophoresis, electroblotted onto a polyvinylidene fluoride (PVDF) membrane, reacted with a TBS-T solution containing 5% skim milk at room temperature for 1 hour, and then reacted with a 5% BSA / TBS-T solution containing rat clone B3, C6, G1 antibodies or mouse anti-DYKDDDDK tag antibody (Fujifilm Wako Pure Chemical Industries, Ltd. Cat#014-22383) at 4°C overnight. After washing with TBS-T solution, the membrane was reacted with 5% skim milk / TBS-T solution containing peroxidase-labeled goat anti-rat IgG antibody (Jackson ImmunoResearch Inc. Cat#112-035-003) or peroxidase-labeled goat anti-mouse IgG antibody (Jackson Immuno Research Inc. Cat#115-035-003) at room temperature for 1 hour. After washing the PVDF membrane with TBS-T solution, the signal obtained by reacting with the peroxidase luminescent reagent was detected using a FUSION camera.

[0126] The results, such as Fig. 9 As shown, it was confirmed that the clone B3, C6, and G1 antibodies all recognized the full-length and truncated mutant CALR proteins.

[0127] (2) Confirmation that the three antibodies recognize mutant CALR proteins on the cell surface

[0128] The mutant CALR protein of Del 52 or Ins 5, which was tagged with a FLAG tag downstream of the amino-terminal signal sequence, was expressed in UT-7 / TPO cells and cultured in IMDM medium containing 10% fetal bovine inactivated serum at 37°C in the presence of 5% CO2. 5After washing with PBS, the cells were reacted with mouse anti-DYKDDDDK tag antibody (Fujifilm Wako Pure Chemical Industries, Ltd. Cat#014-22383) or rat clone B3, C6, G1 antibodies in 2% FBS / PBS solution on ice for 30 minutes. After the reaction, the cells were washed with 2% FBS / PBS solution, and then, as secondary antibodies, anti-mouse IgG-Alexa Fluor647 (Thermo Fisher Scientific, Inc. Cat#A21235) and anti-rat IgG-Alexa Fluor647 (Thermo Fisher Scientific, Inc. Cat#A21247) were reacted in 2% FBS / PBS solution on ice for 30 minutes. After the reaction, the cells were collected by centrifugation and reacted with PBS solution containing 4% paraformaldehyde on ice for 15 minutes. Finally, after adding 2% FBS / PBS solution, the cells were centrifuged (400 g×5 minutes, 4° C.), the supernatant was discarded, and the cells were washed. 300 μL of 2% FBS / PBS solution was added, and the signals were quantified by flow cytometry analysis using FACS Calibur (BD biosciences).

[0129] The results, such as Fig.10 As shown, it was confirmed that clone B3, C6, and G1 antibodies all recognized mutant CALR protein on the cell surface.

[0130] [Test Example 3]

[0131] (Evaluation of Antibody Antigen Binding Ability)

[0132] (1) Evaluation of antigen binding ability using ELISA

[0133] 100 ng of purified Del 52 mutant CALR protein or control BSA was adsorbed to each well, and the obtained ELISA plate (Sumitomo Bakelite Cat#MS-8896F) was reacted with PBS containing 5 mg / mL BSA at room temperature for 1 hour. After washing the wells with PBS, PBS containing 0, 6.25, 12.5, 25, 50, 100, 200, 400, 800 ng / mL of clone B3, C6, G1 antibodies, or rat IgG (Santa Cruz Cat#2026) and 5 mg / mL BSA was reacted at room temperature for 1 hour. After washing the wells with PBS, PBS containing 16 ng / mL peroxidase-labeled goat anti-rat IgG antibody (Jackson Immuno Research Inc. Cat#112-035-003) and 5 mg / mL BSA was reacted at room temperature for 1 hour. After washing the wells with TBS-T solution, TMB solution (NACALAI TESQUE Cat#05298-80) was added and reacted at room temperature for 15 minutes. Then, 1 M aqueous sulfuric acid solution was added and the absorbance at 450 nm and 620 nm was measured. The difference in absorbance was determined and then the value obtained by subtracting the value obtained with the control BSA was calculated.

[0134] The results, such as Fig.11 As shown, it was found that the antibodies of the present invention (B3, C6, G1) all bind to the mutant CALR protein at low concentrations.

[0135] (2) Evaluation of antigen binding ability using surface plasmon resonance analysis

[0136] After the sensor chip for surface plasmon resonance analysis (GE Healthcare Cat#BR100530) was loaded in the surface plasmon resonance analysis device Biacore T200 (GE Healthcare), it was equilibrated with HBS-EP buffer (GE Healthcare Cat#BR100669). Using Amine coupling kit (GE Healthcare Cat#BR100050), the clone B3 antibody prepared with Acetate 5.5 (GE Healthcare Cat#BR100352) at a concentration of 10 μg / mL was immobilized in a manner that the immobilization amount became 200RU. Next, a peptide with cysteine ​​added to the amino terminal of the amino acid sequence (RRMMRTKMR) contained in sequence number 1, prepared at a concentration of 20, 10, 5, 2.5, 1.25 nM using HBS-EP buffer, was used to measure surface plasmon resonance, and the dissociation constant was obtained using Biacore T200Evaluation Software.

[0137] The results, such as Fig.12 As shown, it was found that the antibody of the present invention strongly binds to the mutant CALR protein.

[0138] [Test Example 4]

[0139] (Identification of Antigen Recognition Sites of Antibodies)

[0140] The amino acid sequences used by clone B3, C6, and G1 antibodies to recognize antigens on CALR mutant proteins were confirmed. Fig.13A ) and ELISA ( Fig. 13B ) The reactivity of each antibody to a mutant CALR protein in which the amino acid used as the antigen and the surrounding amino acids were each substituted with alanine was evaluated.

[0141] (1) Immunoblotting

[0142] A protein in which amino acids in the region from threonine (T) at position 367 to arginine (R) at position 378 of the Del 52 mutant CALR protein were substituted one by one with alanine (A), or a protein without substitution was expressed in HEK293T cells, and a culture supernatant containing the secreted mutant CALR protein was prepared by centrifugation (1,600 g × 5 minutes, 4°C). The obtained protein solution was heat-treated in the presence of SDS and a reducing agent, developed on a gel by SDS polyacrylamide electrophoresis, electroblotted onto a PVDF membrane, reacted with a TBS-T solution containing 5% skim milk at room temperature for 1 hour, and then reacted with a 5% BSA / TBS-T solution containing peroxidase-labeled clone B3, C6, G1 antibodies, or mouse anti-CALR antibody (abcam Cat#ab22683) at 4°C overnight. After the PVDF membrane reacted with the mouse anti-CALR antibody, it was washed with a TBS-T solution and then reacted at room temperature for 1 hour in a 5% skim milk / TBS-T solution containing a peroxidase-labeled anti-mouse IgG antibody (Jackson ImmunoResearch Inc. Cat#115-035-003). Then, the entire PVDF membrane was washed with a TBS-T solution, and the signal obtained by the reaction with a peroxidase luminescent reagent (Thermo Fisher Scientific Cat#34094) was detected using a FUSION camera (Vilber-Lourmat).

[0143] The results, such as Fig.13A As shown, it is known that the antibody of the present invention recognizes between the 1st arginine and the 9th arginine in SEQ ID NO: 1.

[0144] (2) ELISA

[0145] The ELISA plate adsorbed with the mutant CALR protein prepared by the above method was reacted with PBS containing 5 mg / mL BSA at room temperature for 1 hour. After washing the wells with PBS, PBS containing 200 ng / mL of clone B3, C6, G1 antibodies or mouse anti-CALR antibody (Cat#sc-373863, Santa Cruz) and 5 mg / mL BSA was reacted at room temperature for 1 hour. After washing the wells with PBS, PBS containing 16 ng / mL of peroxidase-labeled goat anti-rat IgG antibody (Cat#112-035-003, Jackson Immuno Research Inc.) or goat anti-mouse IgG antibody (Cat#sc-2005, Santa Cruz) and 5 mg / mL BSA was reacted at room temperature for 1 hour. After washing the wells with TBS-T solution, TMB solution was added, reacted at room temperature for 15 minutes, and then 1 M sulfuric acid aqueous solution was added, and the absorbance at 450 nm and 620 nm was measured to determine the difference in absorbance.

[0146] The results, such as Fig. 13B As shown, it is known that the antibody of the present invention recognizes between the 1st arginine and the 9th arginine in SEQ ID NO: 1.

[0147] [Test Example 5]

[0148] (Confirmation of sequence information of the antibody of the present invention)

[0149] The sequence information of the heavy and light chains of the antibodies (B3, C6, G1) of the present invention was prepared by using PureLinc RNA Mini Kit (ThermoFisher Cat#12183025) from cells producing the antibodies. The obtained mRNA was used as a template, and a heavy or light chain-specific reverse transcription primer was used to synthesize cDNA using the Rapid amplification of cDNAends method, and then cloned in a plasmid. The full-length sequence of the cDNA of the heavy and light chains was determined by Sanger sequencing analysis of the obtained plasmid.

[0150] The results are shown in Figure 14 to Figure 17 and serial numbers 5 to 34.

[0151] Fig.14 The amino acid sequences of the heavy chain variable regions of the antibodies of the present invention (B3, C6, G1) are shown. Fig.15 The amino acid sequences of the light chain variable regions of the antibodies of the present invention (B3, C6, G1) are shown. Fig.16 Shown are the base sequences of the heavy chain variable regions of the antibodies of the present invention (B3, C6, G1). Fig.17The base sequences of the light chain variable regions of the antibodies of the present invention (B3, C6, G1) are shown.

[0152] Sequence number 5 represents the amino acid sequence of the heavy chain variable region of the B3 antibody. Sequence number 6 represents the amino acid sequence of the heavy chain variable region of the C6 antibody. Sequence number 7 represents the amino acid sequence of the heavy chain variable region of the G1 antibody. Sequence number 8 represents the amino acid sequence of the light chain variable region of the B3 antibody. Sequence number 9 represents the amino acid sequence of the light chain variable region of the C6 antibody. Sequence number 10 represents the amino acid sequence of the light chain variable region of the G1 antibody.

[0153] Sequence number 11 represents the base sequence of the heavy chain variable region of the B3 antibody. Sequence number 12 represents the base sequence of the heavy chain variable region of the C6 antibody. Sequence number 13 represents the base sequence of the heavy chain variable region of the G1 antibody. Sequence number 14 represents the base sequence of the light chain variable region of the B3 antibody. Sequence number 15 represents the base sequence of the light chain variable region of the C6 antibody. Sequence number 16 represents the base sequence of the light chain variable region of the G1 antibody.

[0154] Sequence number 17 represents the amino acid sequence of CDR1 of VH of B3 antibody. Sequence number 18 represents the amino acid sequence of CDR2 of VH of B3 antibody. Sequence number 19 represents the amino acid sequence of CDR3 of VH of B3 antibody. Sequence number 20 represents the amino acid sequence of CDR1 of VH of C6 antibody. Sequence number 21 represents the amino acid sequence of CDR2 of VH of C6 antibody. Sequence number 22 represents the amino acid sequence of CDR3 of VH of C6 antibody. Sequence number 23 represents the amino acid sequence of CDR1 of VH of G1 antibody. Sequence number 24 represents the amino acid sequence of CDR2 of VH of G1 antibody. Sequence number 25 represents the amino acid sequence of CDR3 of VH of G1 antibody. Sequence number 26 represents the amino acid sequence of CDR1 of VL of B3 antibody. Sequence number 27 represents the amino acid sequence of CDR2 of VL of B3 antibody. Sequence number 28 represents the amino acid sequence of CDR3 of VL of B3 antibody. Sequence number 29 represents the amino acid sequence of CDR1 of VL of C6 antibody. Sequence number 30 represents the amino acid sequence of CDR2 of VL of C6 antibody. Sequence number 31 represents the amino acid sequence of CDR3 of VL of C6 antibody. Sequence number 32 represents the amino acid sequence of CDR1 of VL of G1 antibody. Sequence number 33 represents the amino acid sequence of CDR2 of VL of G1 antibody. Sequence number 34 represents the amino acid sequence of CDR3 of VL of G1 antibody.

[0155] [Test Example 6]

[0156] (Evaluation of treatment effect)

[0157] A chimeric B3 antibody was prepared by fusing the heavy and light chain variable regions of the clone B3 antibody with the heavy and light chain constant regions of the corresponding mouse IgG2a. The chimeric antibody was administered to bone marrow proliferative tumor model mice transplanted with hematopoietic stem cells expressing the Del 52-type CALR mutant gene, and the therapeutic effect of the chimeric antibody was evaluated.

[0158] The gene sequence encoding the heavy chain variable region of the clone B3 antibody and the constant region of mouse IgG2a, or the gene sequence encoding the light chain variable region of the clone B3 antibody and the constant region of horse immunoglobulin κ was linked and inserted into the B3 mouse chimera heavy chain and light chain genes to obtain an expression vector, which was introduced into ExpiCHO-S cells (ThermoFisher Cat#A29127), and cultured at 37°C in the presence of 5% CO2 for 10 days using ExpiCHO Expression medium (ThermoFisher Cat#A2910001). After the culture supernatant was recovered by centrifugation (4,000g×30 minutes, 4°C), the chimeric antibody was adsorbed to a HiTrap ProteinG HP column (GE Healthcare Cat#29048581), eluted using 0.1M Glycine-HCl (pH 2.7), and the eluted fraction neutralized with 1M Tris-HCl (pH 9.0) was dialyzed against PBS to prepare B3 mouse chimeric antibody.

[0159] In the evaluation of the therapeutic effect of B3 mouse chimeric antibody, bone marrow transplantation model mice were used. Bone marrow cells were purified from the femur of 8- to 10-week-old B6.CD45.1 syngeneic mice (Sankyo LABO), c-kit-positive cells were isolated and labeled with APC-labeled anti-c-kit antibody, and then LSK cells that were negative for Ter119, CD4, CD8, Gr-1, CD45R, CD3e, and CD11b and positive for CD117 and Sca1 were isolated and infected with a retrovirus containing a pMSCV-IRES-GFP vector expressing a Del 52-type mutant CALR gene or a control vector. 72 hours after infection, 4,000 LSK cells were transplanted into 8- to 10-week-old C57BL / 6J mice (Oriental yeast) irradiated with 6 Gy x 2 times, and the number of platelets in peripheral blood was measured over time using a multi-item automatic blood cell counter (Sysmex Cat#pocH-100iVDiff). After thrombocytosis, a phenotype of myeloid proliferative tumors caused by the expression of the mutant CALR gene, was confirmed in the second month after transplantation, the above-mentioned B3 mouse chimeric antibody was administered weekly at 250 μg per mouse or the solvent (PBS) from the 9th week after transplantation to evaluate the inhibitory effect of B3 mouse chimeric antibody-specific thrombocytosis.

[0160] The results, such as Fig.18 As shown, the antibody of the present invention exhibits excellent therapeutic effect on MPN. Sequence Listing <110> Juntendo Educational Foundation <120> Antibodies that bind to truncated mutant calreticulin and drugs for diagnosis, prevention or treatment of bone marrow proliferative tumors <130> JUSM0023 <150> JP 2019-036119 <151> 2019-02-28 <160> 34 <170> PatentIn version 3.5 <210> 1 <211> 13 <212> PRT <213> Homo sapiens <400> 1 Arg Arg Met Met Arg Thr Lys Met Arg Met Arg Arg Met 1 5 10 <210> 2 <211> 417 <212> PRT <213> Homo sapiens <400> 2 Met Leu Leu Ser Val Pro Leu Leu Leu Gly Leu Leu Gly Leu Ala Val 1 5 10 15 Ala Glu Pro Ala Val Tyr Phe Lys Glu Gln Phe Leu Asp Gly Asp Gly 20 25 30 Trp Thr Ser Arg Trp Ile Glu Ser Lys His Lys Ser Asp Phe Gly Lys 35 40 45 Phe Val Leu Ser Ser Gly Lys Phe Tyr Gly Asp Glu Glu Lys Asp Lys 50 55 60 Gly Leu Gln Thr Ser Gln Asp Ala Arg Phe Tyr Ala Leu Ser Ala Ser 65 70 75 80 Phe Glu Pro Phe Ser Asn Lys Gly Gln Thr Leu Val Val Gln Phe Thr 85 90 95 Val Lys His Glu Gln Asn Ile Asp Cys Gly Gly Gly Tyr Val Lys Leu 100 105 110 Phe Pro Asn Ser Leu Asp Gln Thr Asp Met His Gly Asp Ser Glu Tyr 115 120 125 Asn Ile Met Phe Gly Pro Asp Ile Cys Gly Pro Gly Thr Lys Lys Val 130 135 140 His Val Ile Phe Asn Tyr Lys Gly Lys Asn Val Leu Ile Asn Lys Asp 145 150 155 160 Ile Arg Cys Lys Asp Asp Glu Phe Thr His Leu Tyr Thr Leu Ile Val 165 170 175 Arg Pro Asp Asn Thr Tyr Glu Val Lys Ile Asp Asn Ser Gln Val Glu 180 185 190 Ser Gly Ser Leu Glu Asp Asp Trp Asp Phe Leu Pro Pro Lys Lys Ile 195 200 205 Lys Asp Pro Asp Ala Ser Lys Pro Glu Asp Trp Asp Glu Arg Ala Lys 210 215 220 Ile Asp Asp Pro Thr Asp Ser Lys Pro Glu Asp Trp Asp Lys Pro Glu 225 230 235 240 His Ile Pro Asp Pro Asp Ala Lys Lys Pro Glu Asp Trp Asp Glu Glu 245 250 255 Met Asp Gly Glu Trp Glu Pro Pro Val Ile Gln Asn Pro Glu Tyr Lys 260 265 270 Gly Glu Trp Lys Pro Arg Gln Ile Asp Asn Pro Asp Tyr Lys Gly Thr 275 280 285 Trp Ile His Pro Glu Ile Asp Asn Pro Glu Tyr Ser Pro Asp Pro Ser 290 295 300 Ile Tyr Ala Tyr Asp Asn Phe Gly Val Leu Gly Leu Asp Leu Trp Gln 305 310 315 320 Val Lys Ser Gly Thr Ile Phe Asp Asn Phe Leu Ile Thr Asn Asp Glu 325 330 335 Ala Tyr Ala Glu Glu Phe Gly Asn Glu Thr Trp Gly Val Thr Lys Ala 340 345 350 Ala Glu Lys Gln Met Lys Asp Lys Gln Asp Glu Glu Gln Arg Leu Lys 355 360 365 Glu Glu Glu Glu Asp Lys Lys Arg Lys Glu Glu Glu Glu Ala Glu Asp 370 375 380 Lys Glu Asp Asp Glu Asp Lys Asp Glu Asp Glu Glu Asp Glu Glu Asp 385 390 395 400 Lys Glu Glu Asp Glu Glu Glu Asp Val Pro Gly Gln Ala Lys Asp Glu 405 410 415 Leu <210> 3 <211> 411 <212> PRT <213> Homo sapiens <400> 3 Met Leu Leu Ser Val Pro Leu Leu Leu Gly Leu Leu Gly Leu Ala Val 1 5 10 15 Ala Glu Pro Ala Val Tyr Phe Lys Glu Gln Phe Leu Asp Gly Asp Gly 20 25 30 Trp Thr Ser Arg Trp Ile Glu Ser Lys His Lys Ser Asp Phe Gly Lys 35 40 45 Phe Val Leu Ser Ser Gly Lys Phe Tyr Gly Asp Glu Glu Lys Asp Lys 50 55 60 Gly Leu Gln Thr Ser Gln Asp Ala Arg Phe Tyr Ala Leu Ser Ala Ser 65 70 75 80 Phe Glu Pro Phe Ser Asn Lys Gly Gln Thr Leu Val Val Gln Phe Thr 85 90 95 Val Lys His Glu Gln Asn Ile Asp Cys Gly Gly Gly Tyr Val Lys Leu 100 105 110 Phe Pro Asn Ser Leu Asp Gln Thr Asp Met His Gly Asp Ser Glu Tyr 115 120 125 Asn Ile Met Phe Gly Pro Asp Ile Cys Gly Pro Gly Thr Lys Lys Val 130 135 140 His Val Ile Phe Asn Tyr Lys Gly Lys Asn Val Leu Ile Asn Lys Asp 145 150 155 160 Ile Arg Cys Lys Asp Asp Glu Phe Thr His Leu Tyr Thr Leu Ile Val 165 170 175 Arg Pro Asp Asn Thr Tyr Glu Val Lys Ile Asp Asn Ser Gln Val Glu 180 185 190 Ser Gly Ser Leu Glu Asp Asp Trp Asp Phe Leu Pro Pro Lys Lys Ile 195 200 205 Lys Asp Pro Asp Ala Ser Lys Pro Glu Asp Trp Asp Glu Arg Ala Lys 210 215 220 Ile Asp Asp Pro Thr Asp Ser Lys Pro Glu Asp Trp Asp Lys Pro Glu 225 230 235 240 His Ile Pro Asp Pro Asp Ala Lys Lys Pro Glu Asp Trp Asp Glu Glu 245 250 255 Met Asp Gly Glu Trp Glu Pro Pro Val Ile Gln Asn Pro Glu Tyr Lys 260 265 270 Gly Glu Trp Lys Pro Arg Gln Ile Asp Asn Pro Asp Tyr Lys Gly Thr 275 280 285 Trp Ile His Pro Glu Ile Asp Asn Pro Glu Tyr Ser Pro Asp Pro Ser 290 295 300 Ile Tyr Ala Tyr Asp Asn Phe Gly Val Leu Gly Leu Asp Leu Trp Gln 305 310 315 320 Val Lys Ser Gly Thr Ile Phe Asp Asn Phe Leu Ile Thr Asn Asp Glu 325 330 335 Ala Tyr Ala Glu Glu Phe Gly Asn Glu Thr Trp Gly Val Thr Lys Ala 340 345 350 Ala Glu Lys Gln Met Lys Asp Lys Gln Asp Glu Glu Gln Arg Thr Arg 355 360 365 Arg Met Met Arg Thr Lys Met Arg Met Arg Arg Met Arg Arg Thr Arg 370 375 380 Arg Lys Met Arg Arg Lys Met Ser Pro Ala Arg Pro Arg Thr Ser Cys 385 390 395 400 Arg Glu Ala Cys Leu Gln Gly Trp Thr Glu Ala 405 410 <210> 4 <211> 430 <212> PRT <213> Homo sapiens <400> 4 Met Leu Leu Ser Val Pro Leu Leu Leu Gly Leu Leu Gly Leu Ala Val 1 5 10 15 Ala Glu Pro Ala Val Tyr Phe Lys Glu Gln Phe Leu Asp Gly Asp Gly 20 25 30 Trp Thr Ser Arg Trp Ile Glu Ser Lys His Lys Ser Asp Phe Gly Lys 35 40 45 Phe Val Leu Ser Ser Gly Lys Phe Tyr Gly Asp Glu Glu Lys Asp Lys 50 55 60 Gly Leu Gln Thr Ser Gln Asp Ala Arg Phe Tyr Ala Leu Ser Ala Ser 65 70 75 80 Phe Glu Pro Phe Ser Asn Lys Gly Gln Thr Leu Val Val Gln Phe Thr 85 90 95 Val Lys His Glu Gln Asn Ile Asp Cys Gly Gly Gly Tyr Val Lys Leu 100 105 110 Phe Pro Asn Ser Leu Asp Gln Thr Asp Met His Gly Asp Ser Glu Tyr 115 120 125 Asn Ile Met Phe Gly Pro Asp Ile Cys Gly Pro Gly Thr Lys Lys Val 130 135 140 His Val Ile Phe Asn Tyr Lys Gly Lys Asn Val Leu Ile Asn Lys Asp 145 150 155 160 Ile Arg Cys Lys Asp Asp Glu Phe Thr His Leu Tyr Thr Leu Ile Val 165 170 175 Arg Pro Asp Asn Thr Tyr Glu Val Lys Ile Asp Asn Ser Gln Val Glu 180 185 190 Ser Gly Ser Leu Glu Asp Asp Trp Asp Phe Leu Pro Pro Lys Lys Ile 195 200 205 Lys Asp Pro Asp Ala Ser Lys Pro Glu Asp Trp Asp Glu Arg Ala Lys 210 215 220 Ile Asp Asp Pro Thr Asp Ser Lys Pro Glu Asp Trp Asp Lys Pro Glu 225 230 235 240 His Ile Pro Asp Pro Asp Ala Lys Lys Pro Glu Asp Trp Asp Glu Glu 245 250 255 Met Asp Gly Glu Trp Glu Pro Pro Val Ile Gln Asn Pro Glu Tyr Lys 260 265 270 Gly Glu Trp Lys Pro Arg Gln Ile Asp Asn Pro Asp Tyr Lys Gly Thr 275 280 285 Trp Ile His Pro Glu Ile Asp Asn Pro Glu Tyr Ser Pro Asp Pro Ser 290 295 300 Ile Tyr Ala Tyr Asp Asn Phe Gly Val Leu Gly Leu Asp Leu Trp Gln 305 310 315 320 Val Lys Ser Gly Thr Ile Phe Asp Asn Phe Leu Ile Thr Asn Asp Glu 325 330 335 Ala Tyr Ala Glu Glu Phe Gly Asn Glu Thr Trp Gly Val Thr Lys Ala 340 345 350 Ala Glu Lys Gln Met Lys Asp Lys Gln Asp Glu Glu Gln Arg Leu Lys 355 360 365 Glu Glu Glu Glu Asp Lys Lys Arg Lys Glu Glu Glu Glu Ala Glu Asp 370 375 380 Asn Cys Arg Arg Met Met Arg Thr Lys Met Arg Met Arg Arg Met Arg 385 390 395 400 Arg Thr Arg Arg Lys Met Arg Arg Lys Met Ser Pro Ala Arg Pro Arg 405 410 415 Thr Ser Cys Arg Glu Ala Cys Leu Gln Gly Trp Thr Glu Ala 420 425 430 <210> 5 <211> 119 <212> PRT <213> Rat <400> 5 Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Arg Asn 20 25 30 Phe Ile His Trp Ile Lys Gln Gln Pro Gly Asn Gly Leu Glu Trp Ile 35 40 45 Gly Trp Ile Phe Pro Gly Asp Gly Asp Thr Glu Tyr Asn Gln Lys Phe 50 55 60 Asn Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 85 90 95 Ala Arg Gly Asn Tyr Asn Tyr Glu Tyr Phe Asp Tyr Trp Gly Gln Gly 100 105 110 Val Met Val Thr Val Ser Ser 115 <210> 6 <211> 121 <212> PRT <213> Rat <400> 6 Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Phe Val His Trp Ile Lys Gln Gln Pro Gly Asp Gly Leu Glu Trp Ile 35 40 45 Gly Trp Ile Tyr Pro Gly Asp Gly Asp Thr Glu Tyr Asn His Lys Phe 50 55 60 Asn Gly Lys Ser Thr Leu Thr Ala Asp Arg Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 85 90 95 Ala Arg Gly Asn Tyr Tyr Asp Gly Arg Glu Val Met Asp Ala Trp Gly 100 105 110 Gln Gly Ala Ser Val Thr Val Ser Ser 115 120 <210> 7 <211> 121 <212> PRT <213> Rat <400> 7 Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Phe Val His Trp Ile Lys Gln Gln Pro Gly Asp Gly Leu Glu Trp Ile 35 40 45 Gly Trp Ile Tyr Pro Gly Asp Gly Asp Thr Glu Tyr Asn Gln Lys Phe 50 55 60 Asn Gly Lys Ala Thr Leu Thr Ala Asp Arg Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 85 90 95 Ala Arg Gly Asn Tyr Tyr Asp Gly Arg Glu Val Met Asp Ala Trp Gly 100 105 110 Gln Gly Ala Ser Val Thr Val Ser Ser 115 120 <210> 8 <211> 107 <212> PRT <213> Rat <400> 8 Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Leu Gly 1 5 10 15 Glu Thr Val Ser Ile Glu Cys Leu Ala Ser Glu Asp Ile Tyr Ser Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ser Pro Gln Leu Leu Ile 35 40 45 Phe Ala Ala Asn Arg Leu Gln Asp Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Gln Phe Ser Leu Lys Ile Ser Gly Met Gln Pro 65 70 75 80 Glu Asp Glu Gly Asp Tyr Phe Cys Leu Gln Gly Ser Lys Phe Pro Tyr 85 90 95 Thr Phe Gly Pro Gly Thr Lys Leu Glu Leu Asn 100 105 <210> 9 <211> 112 <212> PRT <213> Rat <400> 9 Asp Val Val Leu Thr Gln Thr Pro Pro Thr Leu Ser Ala Thr Ile Gly 1 5 10 15 Gln Ser Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Asp Ser 20 25 30 Asp Gly Glu Thr Tyr Leu Asn Trp Leu Leu Gln Arg Pro Gly Gln Ser 35 40 45 Pro Gln Leu Leu Ile Tyr Ser Val Ser Asn Leu Glu Ser Gly Val Pro 50 55 60 Asn Arg Phe Ser Gly Ser Gly Ser Glu Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Gly Met Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Met Gln Ala 85 90 95 Thr His Gly Pro Tyr Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 100 105 110 <210> 10 <211> 112 <212> PRT <213> Rat <400> 10 Asp Val Val Leu Thr Gln Thr Pro Pro Thr Leu Ser Ala Thr Ile Gly 1 5 10 15 Gln Ser Val Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Asp Ser 20 25 30 Asp Gly Glu Thr Tyr Leu Asn Trp Leu Leu Gln Arg Pro Gly Gln Cys 35 40 45 Pro Gln Leu Leu Ile Tyr Ser Val Ser Asn Leu Glu Ser Gly Val Pro 50 55 60 Asn Arg Phe Ser Gly Ser Gly Ser Glu Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Gly Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Met Gln Gly 85 90 95 Thr His Gly Pro Tyr Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 100 105 110 <210> 11 <211> 357 <212> DNA <213> Rat <400> 11 caggtacagc tgcagcaatc tggggctgaa ctggtgaagc ctgggtcctc agtgaaaatt 60 tcctgcaagg cttctggcta caccttcacc cgtaacttta tacactggat aaaacagcag 120 cctggaaatg gccttgagtg gattgggtgg atttttcctg gagatggtga tacagagtac 180 aatcaaaagt tcaatgggaa ggcaacactc actgcagaca aatcgtccag cacagcctat 240 atgcagctca gcagcctgac atctgaggac tctgcagtct atttctgtgc aagaggaaat 300 tacaactacg agtactttga ttactggggc caaggagtca tggtcacagt ctcctca 357 <210> 12 <211> 363 <212> DNA <213> Rat <400> 12 caggtacagc tgcagcaatc tggggctgaa ctggtgaagc ctgggtcctc agtgaaaatt 60 tcctgcaagg cttctggcta caccttcacc agttactttg tgcactggat aaaacagcag 120 tcctgcaagg cttctggcta caccttcacc agttactttg tgcactggat aaaacagcag 120 cctggagatg gccttgagtg gattgggtgg atttatcctg gagatggtga tacagagtac 180 cctggagatg gccttgagtg gattgggtgg atttatcctg gagatggtga tacagagtac 180 aatcacaagt tcaatgggaa gtcaacactc actgcagaca gatcctccag tacagcctat 240 aatcacaagt tcaatgggaa gtcaacactc actgcagaca gatcctccag tacagcctat 240 atgcagctca gcagcctgac atctgaggac tctgcagtct atttctgtgc aagagggaat 300 atgcagctca gcagcctgac atctgaggac tctgcagtct atttctgtgc aagagggaat 300 tactatgatg gtcgggaagt tatggatgcc tggggtcaag gagcttcagt cactgtctcc 360 tactatgatg gtcgggaagt tatggatgcc tggggtcaag gagcttcagt cactgtctcc 360 tca 363 tca 363 <210> 13<210> 13 <211> 363<211> 363 <212> DNA<212> DNA <213> 大鼠<213> Rat <400> 13 <400> 13 caggtacagc tgcagcaatc tggggctgaa ctggtgaagc ctgggtcctc agtgaaaatt 60 caggtacagc tgcagcaatc tggggctgaa ctggtgaagc ctgggtcctc agtgaaaatt 60 tcctgcaagg cttctggcta caccttcacc agttactttg tgcactggat aaaacagcag 120 tcctgcaagg cttctggcta caccttcacc agttactttg tgcactggat aaaacagcag 120 cctggagatg gccttgagtg gattgggtgg atttatcctg gagatggtga tacagagtac 180 cctggagatg gccttgagtg gattgggtgg atttatcctg gagatggtga tacagagtac 180 aatcaaaagt tcaatgggaa ggcaacactc actgcagaca gatcctccag tacagcctat 240 aatcaaaagt tcaatgggaa ggcaacactc actgcagaca gatcctccag tacagcctat 240 atgcagctca gcagcctgac atctgaggac tctgcagtct atttctgtgc aagagggaat 300 atgcagctca gcagcctgac atctgaggac tctgcagtct atttctgtgc aagagggaat 300 tactatgatg gtcgggaagt tatggatgcc tggggtcaag gagcttcagt cactgtctcc 360 tca 363 <210> 14 <211> 321 <212> DNA <213> Rat <400> 14 gacatccaga tgacacagtc tccggcttcc ctgtctgcat ctctgggaga aactgtctcc 60 atcgagtgtc tagcaagtga ggacatttac agttatttag catggtatca acagaagcca 120 gggaaatctc ctcagctcct gatctttgct gcaaataggt tgcaagatgg ggtcccatca 180 cggttcagtg gcagtggatc tggcacacag ttttctctca agatcagcgg catgcaacct 240 gaagatgaag gggattattt ctgtctacag ggttccaagt ttccgtacac ctttggacct 300 gggaccaagc tggaactgaa c 321 <210> 15 <211> 336 <212> DNA <213> Rat <400> 15 gatgttgtgc tgacccagac tccacccact ttatcggcta ccattggaca atcggtctcc 60 atctcttgca ggtcaagtca gagtctctta gatagtgatg gagaaaccta tttaaattgg 120 ttgctacaga ggccaggcca atctccacag cttctaattt attcggtctc caacctggaa 180 tctggggtcc ccaacaggtt cagtggcagt gggtcagaaa cagatttcac actcaaaatc 240 agtggaatgg aggctgaaga tttgggagtt tactactgca tgcaagctac ccatggtccg 300 tacacgtttg gagctgggac caagctggaa ctgaaa 336 <210> 16 <211> 336 <212> DNA <213> Rat <400> 16 gatgttgtgc tgacccagac tccacccact ttatcggcta ccattggaca atcggtctcc 60 atctcttgca ggtcaagtca gagtctctta gatagtgatg gagaaaccta tttaaattgg 120 ttgctacaga ggccaggcca atgtccacag cttctaattt attcggtatc caacctggaa 180 tctggggtcc ccaacaggtt cagtggcagt gggtcagaaa cagatttcac actcaaaatc 240 agtggagtgg aggctgaaga tttgggagtt tactactgca tgcaaggtac ccatggtccg 300 tacacgtttg gagctgggac caagctggaa ctgaaa 336 <210> 17 <211> 10 <212> PRT <213> Rat <400> 17 Gly Tyr Thr Phe Thr Arg Asn Phe Ile His 1 5 10 <210> 18 <211> 17 <212> PRT <213> Rat <400> 18 Trp Ile Phe Pro Gly Asp Gly Asp Thr Glu Tyr Asn Gln Lys Phe Asn 1 5 10 15 Gly <210> 19 <211> 10 <212> PRT <213> Rat <400> 19 Gly Asn Tyr Asn Tyr Glu Tyr Phe Asp Tyr 1 5 10 <210> 20 <211> 10 <212> PRT <213> Rat <400> 20 Gly Tyr Thr Phe Thr Ser Tyr Phe Val His 1 5 10 <210> 21 <211> 17 <212> PRT <213> Rat <400> 21 Trp Ile Tyr Pro Gly Asp Gly Asp Thr Glu Tyr Asn His Lys Phe Asn 1 5 10 15 Gly <210> 22 <211> 12 <212> PRT <213> Rat <400> 22 Gly Asn Tyr Tyr Asp Gly Arg Glu Val Met Asp Ala 1 5 10 <210> 23 <211> 10 <212> PRT <213> Rat <400> twenty three Gly Tyr Thr Phe Thr Ser Tyr Phe Val His 1 5 10 <210> twenty four <211> 17 <212> PRT <213> Rat <400> twenty four Trp Ile Tyr Pro Gly Asp Gly Asp Thr Glu Tyr Asn Gln Lys Phe Asn 1 5 10 15 Gly <210> 25 <211> 12 <212> PRT <213> Rat <400> 25 Gly Asn Tyr Tyr Asp Gly Arg Glu Val Met Asp Ala 1 5 10 <210> 26 <211> 11 <212> PRT <213> Rat <400> 26 Leu Ala Ser Glu Asp Ile Tyr Ser Tyr Leu Ala 1 5 10 <210> 27 <211> 7 <212> PRT <213> Rat <400> 27 Ala Ala Asn Arg Leu Gln Asp 1 5 <210> 28 <211> 9 <212> PRT <213> Rat <400> 28 Leu Gln Gly Ser Lys Phe Pro Tyr Thr 1 5 <210> 29 <211> 16 <212> PRT <213> Rat <400> 29 Arg Ser Ser Gln Ser Leu Leu Asp Ser Asp Gly Glu Thr Tyr Leu Asn 1 5 10 15 <210> 30 <211> 7 <212> PRT <213> Rat <400> 30 Ser Val Ser Asn Leu Glu Ser 1 5 <210> 31 <211> 9 <212> PRT <213> Rat <400> 31 Met Gln Ala Thr His Gly Pro Tyr Thr 1 5 <210> 32 <211> 16 <212> PRT <213> Rat <400> 32 Arg Ser Ser Gln Ser Leu Leu Asp Ser Asp Gly Glu Thr Tyr Leu Asn 1 5 10 15 <210> 33 <211> 7 <212> PRT <213> Rat <400> 33 Ser Val Ser Asn Leu Glu Ser 1 5 <210> 34 <211> 9 <212> PRT <213> Rat <400> 34 Met Gln Gly Thr His Gly Pro Tyr Thr 1 5

Claims

1. An antibody or a functional fragment thereof that binds to a truncated mutant CALR protein, characterized in that: (a) having an antigen recognition site for a polypeptide chain consisting of the amino acid sequence shown in SEQ ID NO: 1, The antibody or functional fragment thereof that binds to the cleaved mutant CALR protein is the following (c): (c) An antibody in which CDR1, CDR2 and CDR3 of the immunoglobulin VH chain are polypeptides consisting of the amino acid sequences shown in SEQ ID NOs: 17, 18 and 19, respectively, and CDR1, CDR2 and CDR3 of the immunoglobulin VL chain are polypeptides consisting of the amino acid sequences shown in SEQ ID NOs: 26, 27 and 28, respectively.

2. The antibody or functional fragment thereof that binds to the cleaved mutant CALR protein according to claim 1, wherein: It is the following (C): (C) An antibody having an immunoglobulin VH chain consisting of the amino acid sequence shown in SEQ ID NO:5 and an immunoglobulin VL chain consisting of the amino acid sequence shown in SEQ ID NO:

8.

3. The antibody or functional fragment thereof according to claim 1 or 2, characterized in that: Used for the diagnosis of bone marrow proliferative tumors.

4. A pharmaceutical composition, characterized in that: A composition comprising the antibody or a functional fragment thereof according to any one of claims 1 to 3.

5. The pharmaceutical composition according to claim 4, characterized in that: It is a diagnostic, preventive or therapeutic drug for bone marrow proliferative tumors.

6. Use of the antibody or functional fragment thereof according to claim 1 or 2 for producing a detection agent for a mutant CALR protein having (a) a polypeptide chain consisting of the amino acid sequence shown in SEQ ID NO:

1.

7. Use of the antibody or functional fragment thereof according to claim 1 or 2 for producing a preventive or therapeutic drug for bone marrow proliferative tumors.

8. Use of the antibody or functional fragment thereof according to claim 1 or 2 in the manufacture of a diagnostic drug for bone marrow proliferative tumors.